PLSE
Pulse Biosciences, Inc. Health Care Surgical & Medical Instruments & Apparatus Russell 3000
$52.24Close
$3.5BMarket cap
$12.66 – $55.4852-week range
Nov 5, 2026Next report · after the close
Highlights
Strengths
- In a stage-2 uptrend all 8 trend conditions pass
- Leading the market RS 99 · stronger than 99% of stocks over 12 months
- Volume drying up last 10 days 31% under the 50-day average
Cautions
- Results soon Nov 5, 2026, in 4 days
Price
Filing Results Screen pick 52-week high and low Adjusted prices
Key figures
Off 12-month high
6%
1wk
down 1.5%
price change
1mo
up 4.6%
price change
12-month return
up 209%
market up 11% ·
its own up 194%
F-score
—
— Not assessed
Altman Z
144.58
Low risk
P/E
—
price / earnings
PEG
—
P/E / EPS growth
P/B
43.9×
price / book
Earnings yield
down 2.2%
EBIT / enterprise value
Cheaper than
13%
of the market · expensive
Revenue growth
—
year on year
EPS growth
—
latest quarter
Sales growth
—
latest quarter
ROE
down 74%
return on equity
Free cash margin
down 15553%
-$54.4M FCF
D/E
—
long-term debt / equity
Net debt / EBITDA
—
Interest cover
—EBIT / interest
Trade setup
ATR%
6.1%
$3.17 a day · 2×ATR $45.91
RS
99 / 99
vs the universe
Trend
8 / 8
trend template
Relative volume
0.9×
vs 50-day average
Up/down volume
1.06
50 sessions
Implied move
—
no option chain · report Nov 5, 2026
Trend template · 8 of 8
Screen verdict
Did not qualify for any screen.
Warning signs
- Shareholders diluted The share count rose 2.9% over the year, from 66m to 68m shares. Each existing share owns a smaller fraction of the company than it did a year ago.
Last reported
Aug 6, 2026
Results reaction
Aug 6, 2026+11% vs market2 sessions after results
Financials
- Gross -54%
- Net -20795%
- Free cash -15553%
- Cash
- Long-term debt
| FY2020Dec 31, 2020 | FY2021Dec 31, 2021 | FY2022Dec 31, 2022 | FY2023Dec 31, 2023 | FY2024Dec 31, 2024 | FY2025Dec 31, 2025 | |
|---|---|---|---|---|---|---|
| Revenue | $0 | $1.4M | $700,000 | $0 | $0 | $350,000 |
| Gross margin | — | -39% | -1606% | — | — | -54% |
| Operating income | -$50.0M | -$63.0M | -$58.1M | -$43.6M | -$56.3M | -$76.9M |
| Net income | -$49.9M | -$63.7M | -$58.5M | -$42.2M | -$53.6M | -$72.8M |
| Net margin | — | -4489% | -8358% | — | — | -20795% |
| Earnings per share | -$2.14 | -$2.28 | -$1.72 | -$0.85 | -$0.92 | -$1.08 |
| Free cash flow | -$35.8M | -$54.5M | -$47.4M | -$33.2M | -$36.5M | -$54.4M |
| Free cash margin | — | -3846% | -6773% | — | — | -15553% |
| Cash | $12.5M | $44.4M | $61.1M | $44.4M | $118.0M | $80.7M |
| Long-term debt | — | — | $65.0M | $0 | — | — |
| Shareholders' equity | $22.9M | $44.4M | -$2.2M | $44.4M | $114.9M | $80.7M |
| Shares outstanding | 25.55m | 55.14m | 37.23m | 55.14m | 65.93m | 67.84m |
Filings
| Filed | Report | Period to | Lag |
|---|---|---|---|
| Aug 6, 2026 | Quarterly ↗ | Jun 30, 2026 | 37d |
| May 14, 2026 | Quarterly ↗ | Mar 31, 2026 | 44d |
| Feb 19, 2026 | Annual ↗ | Dec 31, 2025 | 50d |
| Nov 5, 2025 | Quarterly ↗ | Sep 30, 2025 | 36d |
| Aug 12, 2025 | Quarterly ↗ | Jun 30, 2025 | 43d |
| May 8, 2025 | Quarterly ↗ | Mar 31, 2025 | 38d |
| Mar 31, 2025 | Annual ↗ | Dec 31, 2024 | 90d |
| Oct 30, 2024 | Quarterly ↗ | Sep 30, 2024 | 30d |
| Aug 19, 2024 | Quarterly ↗ | Jun 30, 2024 | 50d |
| May 7, 2024 | Quarterly ↗ | Mar 31, 2024 | 37d |
| Mar 28, 2024 | Annual ↗ | Dec 31, 2023 | 88d |
| Nov 13, 2023 | Quarterly ↗ | Sep 30, 2023 | 44d |
Current reports
| Filed | Disclosed |
|---|---|
| Oct 14, 2026 | Other events ↗ |
| Oct 7, 2026 | Other events ↗ |
| Sep 15, 2026 | Material agreement · Agreement ended ↗ |
| Sep 15, 2026 | Other events ↗ |
| Aug 6, 2026 | Material agreement ↗ |
| Aug 6, 2026 | Results ↗ |
| Jul 29, 2026 | Other events ↗ |
| Jun 12, 2026 | Shareholder vote ↗ |
| Jun 10, 2026 | Other events ↗ |
| May 6, 2026 | Other events ↗ |
| May 4, 2026 | Results · Other events ↗ |
| Apr 27, 2026 | Regulation FD ↗ |